Hemab Therapeutics Holdings, Inc., was incorporated under the laws of the State of Delaware on February 12, 2026. Hemab Therapeutics is a clinical-stage biotechnology company developing therapies that revolutionize the treatment of blood coagulation disorders to help sustain life and enhance human resistance. The company's mission is to build a leading coagulation company for patients with severe bleeding and thrombotic diseases worldwide by discovering, developing and commercializing innovative therapies. These diseases include Grignard's thrombocytopenia, VII factor deficiency, vascular hemophilia, and other abnormal bleeding disorders that can cause a heavy lifelong burden. The Company's lead drug candidate sutacimig (HMB-001), a bispecific antibody, is currently undergoing a Phase I/II clinical trial for the preventive treatment of Grignard's thrombocytopenia and a Phase II clinical trial for the preventive treatment of factor VII deficiency. 

Hemab Therapeutics's 15-minute chart has triggered a KDJ Death Cross and a Bearish Marubozu pattern at 09/10/2026 14:00. This indicates a shift in the momentum of the stock price towards the downside, with a potential for further decreases. Sellers are currently in control of the market, and the bearish momentum is likely to persist.On September 10, 2026, at 14:00, the 15-minute candlestick chart for Hemab Therapeutics Holdings (HEMAB) displayed two notable bearish signals: a KDJ Death Cross and a Bearish Marubozu pattern. These technical indicators suggest a shift in momentum toward the downside, signaling increased selling pressure and a potential continuation of the downward trend. The KDJ Death Cross typically indicates weakening bullish momentum, while the Bearish Marubozu reinforces <a href="https://www.google.com/goto?url=CAESggEB6zswFYp6CmRpfCh21UN7sBL9XT9QufQsYeKRLXljetVKG5ztivsMTgwjqPIG_DLVpRLPr-r3Nh01pfkdWdcHjyYnFDya5os46N3Md5tAQliIoJcWS9hpQ5ifzMvVv9C5Gamqyk9iACGkX462yqPA1SHLO_s9H0XY8T0WbtYkYfTM">dominance of sellers during the period</a>.Market participants should remain cautious as these patterns often precede further price declines. While technical analysis does not guarantee future price movements, the convergence of these signals highlights a short-term bearish bias. Investors are advised to monitor subsequent price action and volume for confirmation of the trend’s persistence. As always, a comprehensive analysis incorporating fundamental and broader market conditions is recommended before making investment decisions.

Hemab Therapeutics

Hemab Therapeutics's 15min chart shows KDJ Death Cross, Bearish Marubozu pattern.

Hemab Therapeutics's 15-minute chart has triggered an expanding downward trend within its Bollinger Bands, accompanied by a KDJ death cross on September 10, 2026, at 12:30. This suggests that the market trend is currently dominated by sellers, with a downward momentum in the stock price that has the potential to further decrease.Hemab Therapeutics Holdings, Inc. (COAG) has experienced a notable decline in its stock price, with shares falling 6.17% as of September 10, 2026, to close at $41.76. The stock has traded within a day's range of $41.65 to $44.51, reflecting heightened volatility. Over the past month, the stock has declined by 16.27%, while its 52-week range remains between $23.00 and $55.42. The company's market capitalization currently stands at $1.95 billion, with a trailing twelve-month (TTM) <a href="https://www.google.com/goto?url=CAESXQHrOzAV_sOn1ysRkum6-1w7y_M48qLdKlOnBfjvrvCVktThvrPGLTGCFIo8uslp7TgFEm1DTsxhTN51vOj-7wtg8_9I62L5D5w9wuNhcZrfXg95sRhHmuKngsT_ng">earnings per share (EPS) of -$1.78</a>, indicating ongoing losses.Technical indicators suggest a bearish trend, with the stock's 15-minute chart showing an expanding downward movement within Bollinger Bands and a KDJ death cross recorded at 12:30 on September 10, 2026. These signals indicate that selling pressure is currently dominant, and the stock may continue to trend downward in the near term. Analysts have set an <a href="https://www.google.com/goto?url=CAESXQHrOzAV_sOn1ysRkum6-1w7y_M48qLdKlOnBfjvrvCVktThvrPGLTGCFIo8uslp7TgFEm1DTsxhTN51vOj-7wtg8_9I62L5D5w9wuNhcZrfXg95sRhHmuKngsT_ng">average price target of $61.20</a>, with the highest target at $65.00, but the current price remains below these estimates.Hemab Therapeutics continues to advance its pipeline, with HMB-001 and HMB-002 in Phase 1/2 clinical trials for rare bleeding disorders. The company remains in a growth phase, with no revenue reported and ongoing research and development expenses. Investors are advised to monitor upcoming earnings and clinical developments for potential catalysts.

Hemab Therapeutics's 15min chart triggers Bollinger Bands Expanding Downward, KDJ Death Cross.

According to Hemab Therapeutics' 15-minute chart, the Bollinger Bands have expanded downward, indicating a bearish trend. The recent bearish Marubozu candle at 09/10/2026 11:45 suggests that sellers are driving the market momentum, which is likely to persist.On September 10, 2026, technical analysis of Hemab Therapeutics Holdings, Inc. (HEMB) indicates a bearish trend based on the 15-minute chart. The Bollinger Bands have expanded downward, signaling increased volatility and a potential continuation of downward momentum. Additionally, a bearish Marubozu candle formed at 11:45, suggesting strong selling pressure with little to no buying activity during the period. This pattern implies that sellers are currently in control, and the downward trajectory may persist in the near term.The technical indicators available for HEMB include MACD, RSI, KDJ, and others, which can provide further <a href="https://www.google.com/goto?url=CAEScAHrOzAVUlbl07QPZ3jlcUn5lQ6mq8TP9OPRI6Q-BxoZPQu9rl-OAMiGLr6LgD967-c7V-KAnbzIrwOdnouOSNV_Iqp_BQSrQ-531rfWoZDrwC2YfSgbg2QUOr-2czWujLzp8WJdaLG8tccuM7q5ivA">insight into market direction</a> and value assessment. However, it is important to note that technical analysis should be used as a reference and not as a definitive predictor of market movements. Investors are advised to consider multiple factors and consult additional analyses before making investment decisions.

Hemab Therapeutics' 15min Chart Triggers Bearish Bollinger Bands Expansion

Hemab Therapeutics's 15-minute chart has triggered a MACD Death Cross and KDJ Death Cross on September 9th, 2026 at 10:30. This indicates that the stock price has the potential to continue declining, with a shift in momentum towards the downside and a likelihood of further decrease.On September 9, 2026, at 10:30, Hemab Therapeutics' 15-minute chart triggered both a MACD Death Cross and a KDJ Death Cross, signaling a potential continuation of downward price movement. The MACD Death Cross occurs when the MACD line crosses below the signal line, typically indicating a bearish shift in momentum. Similarly, the KDJ Death Cross, where the K line crosses below the D line, reinforces [the likelihood of further price declines][1]. These technical indicators are commonly used by traders to assess market sentiment and potential trend reversals. Investors are advised to monitor the stock closely for confirmation signals and to consider broader market conditions before making trading decisions. While technical analysis can provide insights into short-term price behavior, it should not be the sole basis for investment choices. Market conditions can change rapidly, and additional factors, including company fundamentals and macroeconomic trends, should also be evaluated.

Hemab Therapeutics' Stock Price Falls Amid MACD and KDJ Death Crosses

According to the 15-minute chart of Hemab Therapeutics, the Moving Average Convergence Divergence (MACD) and Kinetick/Dynamic (KDJ) indicators have both triggered a "Death Cross" at 09:08 on August 26, 2026, at 14:15. This suggests that the stock price is likely to continue its downward trend, with momentum shifting towards the downside and potentially leading to further decreases.On August 26, 2026, at 14:15, the 15-minute chart for Hemab Therapeutics showed the Moving Average Convergence Divergence (MACD) and Kinetick/Dynamic (KDJ) indicators both forming a "death cross," <a href="https://www.google.com/goto?url=CAESawHrOzAVpMBmLYKFjFLA1mbfKFv39whKDdLJ5q9avQLPCrpp2RZZ9iKzl4bSDwJ9yRPh-nBTbPEqI4jzc9Bz5WJ8l92p_lVrzjvJ0iCDKC1saYjzGCUvZZDsYw35-TTZPlI7vKsqBMEYPSxg">short-term moving average crosses below</a> a long-term moving average. This event occurred at 09:08 and is typically interpreted as a bearish signal, suggesting that <a href="https://www.google.com/goto?url=CAESawHrOzAVpMBmLYKFjFLA1mbfKFv39whKDdLJ5q9avQLPCrpp2RZZ9iKzl4bSDwJ9yRPh-nBTbPEqI4jzc9Bz5WJ8l92p_lVrzjvJ0iCDKC1saYjzGCUvZZDsYw35-TTZPlI7vKsqBMEYPSxg">the stock may continue its downward trend</a>.The death cross is often viewed as an indicator of deteriorating price momentum and is associated with <a href="https://www.google.com/goto?url=CAESawHrOzAVpMBmLYKFjFLA1mbfKFv39whKDdLJ5q9avQLPCrpp2RZZ9iKzl4bSDwJ9yRPh-nBTbPEqI4jzc9Bz5WJ8l92p_lVrzjvJ0iCDKC1saYjzGCUvZZDsYw35-TTZPlI7vKsqBMEYPSxg">potential continuation of a downward trend</a>. While it is not a definitive predictor of future price movements, it is considered <a href="https://www.google.com/goto?url=CAESawHrOzAVpMBmLYKFjFLA1mbfKFv39whKDdLJ5q9avQLPCrpp2RZZ9iKzl4bSDwJ9yRPh-nBTbPEqI4jzc9Bz5WJ8l92p_lVrzjvJ0iCDKC1saYjzGCUvZZDsYw35-TTZPlI7vKsqBMEYPSxg">a coincident indicator of market weakness</a>. Historical data suggests that the death cross has occasionally preceded bear markets, but it has also been <a href="https://www.google.com/goto?url=CAESawHrOzAVpMBmLYKFjFLA1mbfKFv39whKDdLJ5q9avQLPCrpp2RZZ9iKzl4bSDwJ9yRPh-nBTbPEqI4jzc9Bz5WJ8l92p_lVrzjvJ0iCDKC1saYjzGCUvZZDsYw35-TTZPlI7vKsqBMEYPSxg">followed by short-term rebounds and gains</a>.Investors are advised to consider the death cross in conjunction with broader market conditions and fundamental analysis. The pattern should not be used in isolation for investment decisions, as <a href="https://www.google.com/goto?url=CAESawHrOzAVpMBmLYKFjFLA1mbfKFv39whKDdLJ5q9avQLPCrpp2RZZ9iKzl4bSDwJ9yRPh-nBTbPEqI4jzc9Bz5WJ8l92p_lVrzjvJ0iCDKC1saYjzGCUvZZDsYw35-TTZPlI7vKsqBMEYPSxg">its predictive power can diminish</a> over time as market participants adjust their strategies.

COAG News